Radioimmunodetection of human colon cancer in nude mice by a new monoclonal antibody A7 against human colorectal cancer

Determination of modulation of ligand properties of synthetic complex‐type biantennary N‐glycans by introduction of bisecting GlcNAc in silico, in vitro and in vivo

“…Incorporation of 125 I into the neoglycoproteins to a specific activity of 11.5 MBq·(mg protein) −1 was achieved by the chloramine‐T method using limiting amounts of reagents [50]. The retention of radioactivity in organs of Ehrlich‐solid‐tumor‐bearing ddY mice (7 weeks old; Nihon Clea Co., Tokyo, Japan) after injection of 28.75 kBq per animal into the tail vein was determined by a γ‐counter (Aloka ARC 300, Tokyo, Japan) and expressed as percentage of the injected dose per gram of wet tissue or per milliliter of blood for a group of four mice for each type of neoglycoprotein and for each time point, as described [37,51,52].…”

Neoglycoproteins with the Synthetic Complex Biantennary Nonasaccharide or Its α2,3/α2,6-Sialylated Derivatives: Their Preparation, Assessment of Their Ligand Properties for Purified Lectins, for Tumor Cells in Vitro, and in Tissue Sections, and Their Biodistribution in Tumor-Bearing Mice

“…Organ Distribution of Radioiodinated Neoglycoproteins. Incorporation of 125 I into the neoglycoproteins to reach a specific activity of 11.5 MBq/mg of protein was achieved by the chloramine-T method using limiting amounts of reagents (31). The retention of radioactivity in Ehrlich solid tumor-bearing ddY mice (7 weeks old; Nihon Clea Co., Tokyo, Japan) after injection of 28.75 kBq/animal into the tail vain was determined by a γ-counter (Aloka ARC 300, Tokyo, Japan) and expressed as percentage of the injected dose per gram of wet tissue or per milliliter of blood for a group of three to four mice for each type of neoglycoprotein and for each time point, as described (32).…”

Anti‐tumor activity of T‐2 toxin‐conjugated A7 monoclonal antibody (T‐2‐A7 MoAb) against human colon carcinoma

“…We studied the in vivo localization of A7 MoAb in various tumor xenografts, and suggested that A7 MoAb would be applicable to the in vivo radioimmunodetection of human colon cancer [Kojima et al, 1991;Shimura et al, 19921. As shown in Figure 2, human colon cancer LSI 74T was clearly visualized with I3'I-A7 MoAb.…”

“…Of these, monoclonal antibodies recognizing tumor-associated antigens seem to be among the most suitable carriers for cytotoxic agents such as anti-cancer drugs, toxins, and radioisotopes. We have prepared a new monoclonal antibody A7 against human colon cancer, and suggested its potential usefulness for the in vivo radioimmunodetection of human colon cancer [Kojima et al, 1991;Shimura et al, 19921. It could also be a candidate as a drug carrier.…”